Endothelial dysfunction and low-grade inflammation in the transition to renal replacement therapy.

<h4>Introduction</h4>End-stage renal disease (ESRD) strongly associates with cardiovascular disease (CVD) risk. This risk is not completely mitigated by renal replacement therapy. Endothelial dysfunction (ED) and low-grade inflammation (LGI) may contribute to the increased CVD risk. Howe...

Full description

Bibliographic Details
Main Authors: April C E van Gennip, Natascha J H Broers, Karlien J Ter Meulen, Bernard Canaud, Maarten H L Christiaans, Tom Cornelis, Mariëlle A C J Gelens, Marc M H Hermans, Constantijn J A M Konings, Jeroen B van der Net, Frank M van der Sande, Casper G Schalkwijk, Frank Stifft, Joris J J M Wirtz, Jeroen P Kooman, Remy J H Martens
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2019-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0222547
id doaj-783ee53c2bd44954a79d16e4b0e16d82
record_format Article
spelling doaj-783ee53c2bd44954a79d16e4b0e16d822021-03-04T10:24:30ZengPublic Library of Science (PLoS)PLoS ONE1932-62032019-01-01149e022254710.1371/journal.pone.0222547Endothelial dysfunction and low-grade inflammation in the transition to renal replacement therapy.April C E van GennipNatascha J H BroersKarlien J Ter MeulenBernard CanaudMaarten H L ChristiaansTom CornelisMariëlle A C J GelensMarc M H HermansConstantijn J A M KoningsJeroen B van der NetFrank M van der SandeCasper G SchalkwijkFrank StifftJoris J J M WirtzJeroen P KoomanRemy J H Martens<h4>Introduction</h4>End-stage renal disease (ESRD) strongly associates with cardiovascular disease (CVD) risk. This risk is not completely mitigated by renal replacement therapy. Endothelial dysfunction (ED) and low-grade inflammation (LGI) may contribute to the increased CVD risk. However, data on serum biomarkers of ED and LGI during the transition to renal replacement therapy (dialysis and kidney transplantation) are scarce.<h4>Methods</h4>We compared serum biomarkers of ED and LGI between 36 controls, 43 participants with chronic kidney disease (CKD) stage 5 non-dialysis (CKD5-ND), 20 participants with CKD stage 5 hemodialysis (CKD5-HD) and 14 participants with CKD stage 5 peritoneal dialysis (CKD5-PD). Further, in 34 and 15 participants repeated measurements were available during the first six months following dialysis initiation and kidney transplantation, respectively. Serum biomarkers of ED (sVCAM-1, E-selectin, P-selectin, thrombomodulin, sICAM-1, sICAM-3) and LGI (hs-CRP, SAA, IL-6, IL-8, TNF-α) were measured with a single- or multiplex array detection system based on electro-chemiluminescence technology.<h4>Results</h4>In linear regression analyses adjusted for potential confounders, participants with ESRD had higher levels of most serum biomarkers of ED and LGI than controls. In addition, in CKD5-HD levels of serum biomarkers of ED and LGI were largely similar to those in CKD5-ND. In contrast, in CKD5-PD levels of biomarkers of ED were higher than in CKD5-ND and CKD5-HD. Similarly, in linear mixed model analyses sVCAM-1, thrombomodulin, sICAM-1 and sICAM-3 increased after PD initiation. In contrast, incident HD patients showed an increase in sVCAM-1, P-selectin and TNF-α, but a decline of hs-CRP, SAA and IL-6. Further, following kidney transplantation sVCAM-1, thrombomodulin, sICAM-3 and TNF-α were lower at three months post-transplantation and remained stable in the three months thereafter.<h4>Conclusions</h4>Levels of serum biomarkers of ED and LGI were higher in ESRD as compared with controls. In addition, PD initiation and, less convincingly, HD initiation may increase levels of selected serum biomarkers of ED and LGI on top of uremia per se. In contrast to dialysis, several serum biomarkers of ED and LGI markedly declined following kidney transplantation.https://doi.org/10.1371/journal.pone.0222547
collection DOAJ
language English
format Article
sources DOAJ
author April C E van Gennip
Natascha J H Broers
Karlien J Ter Meulen
Bernard Canaud
Maarten H L Christiaans
Tom Cornelis
Mariëlle A C J Gelens
Marc M H Hermans
Constantijn J A M Konings
Jeroen B van der Net
Frank M van der Sande
Casper G Schalkwijk
Frank Stifft
Joris J J M Wirtz
Jeroen P Kooman
Remy J H Martens
spellingShingle April C E van Gennip
Natascha J H Broers
Karlien J Ter Meulen
Bernard Canaud
Maarten H L Christiaans
Tom Cornelis
Mariëlle A C J Gelens
Marc M H Hermans
Constantijn J A M Konings
Jeroen B van der Net
Frank M van der Sande
Casper G Schalkwijk
Frank Stifft
Joris J J M Wirtz
Jeroen P Kooman
Remy J H Martens
Endothelial dysfunction and low-grade inflammation in the transition to renal replacement therapy.
PLoS ONE
author_facet April C E van Gennip
Natascha J H Broers
Karlien J Ter Meulen
Bernard Canaud
Maarten H L Christiaans
Tom Cornelis
Mariëlle A C J Gelens
Marc M H Hermans
Constantijn J A M Konings
Jeroen B van der Net
Frank M van der Sande
Casper G Schalkwijk
Frank Stifft
Joris J J M Wirtz
Jeroen P Kooman
Remy J H Martens
author_sort April C E van Gennip
title Endothelial dysfunction and low-grade inflammation in the transition to renal replacement therapy.
title_short Endothelial dysfunction and low-grade inflammation in the transition to renal replacement therapy.
title_full Endothelial dysfunction and low-grade inflammation in the transition to renal replacement therapy.
title_fullStr Endothelial dysfunction and low-grade inflammation in the transition to renal replacement therapy.
title_full_unstemmed Endothelial dysfunction and low-grade inflammation in the transition to renal replacement therapy.
title_sort endothelial dysfunction and low-grade inflammation in the transition to renal replacement therapy.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2019-01-01
description <h4>Introduction</h4>End-stage renal disease (ESRD) strongly associates with cardiovascular disease (CVD) risk. This risk is not completely mitigated by renal replacement therapy. Endothelial dysfunction (ED) and low-grade inflammation (LGI) may contribute to the increased CVD risk. However, data on serum biomarkers of ED and LGI during the transition to renal replacement therapy (dialysis and kidney transplantation) are scarce.<h4>Methods</h4>We compared serum biomarkers of ED and LGI between 36 controls, 43 participants with chronic kidney disease (CKD) stage 5 non-dialysis (CKD5-ND), 20 participants with CKD stage 5 hemodialysis (CKD5-HD) and 14 participants with CKD stage 5 peritoneal dialysis (CKD5-PD). Further, in 34 and 15 participants repeated measurements were available during the first six months following dialysis initiation and kidney transplantation, respectively. Serum biomarkers of ED (sVCAM-1, E-selectin, P-selectin, thrombomodulin, sICAM-1, sICAM-3) and LGI (hs-CRP, SAA, IL-6, IL-8, TNF-α) were measured with a single- or multiplex array detection system based on electro-chemiluminescence technology.<h4>Results</h4>In linear regression analyses adjusted for potential confounders, participants with ESRD had higher levels of most serum biomarkers of ED and LGI than controls. In addition, in CKD5-HD levels of serum biomarkers of ED and LGI were largely similar to those in CKD5-ND. In contrast, in CKD5-PD levels of biomarkers of ED were higher than in CKD5-ND and CKD5-HD. Similarly, in linear mixed model analyses sVCAM-1, thrombomodulin, sICAM-1 and sICAM-3 increased after PD initiation. In contrast, incident HD patients showed an increase in sVCAM-1, P-selectin and TNF-α, but a decline of hs-CRP, SAA and IL-6. Further, following kidney transplantation sVCAM-1, thrombomodulin, sICAM-3 and TNF-α were lower at three months post-transplantation and remained stable in the three months thereafter.<h4>Conclusions</h4>Levels of serum biomarkers of ED and LGI were higher in ESRD as compared with controls. In addition, PD initiation and, less convincingly, HD initiation may increase levels of selected serum biomarkers of ED and LGI on top of uremia per se. In contrast to dialysis, several serum biomarkers of ED and LGI markedly declined following kidney transplantation.
url https://doi.org/10.1371/journal.pone.0222547
work_keys_str_mv AT aprilcevangennip endothelialdysfunctionandlowgradeinflammationinthetransitiontorenalreplacementtherapy
AT nataschajhbroers endothelialdysfunctionandlowgradeinflammationinthetransitiontorenalreplacementtherapy
AT karlienjtermeulen endothelialdysfunctionandlowgradeinflammationinthetransitiontorenalreplacementtherapy
AT bernardcanaud endothelialdysfunctionandlowgradeinflammationinthetransitiontorenalreplacementtherapy
AT maartenhlchristiaans endothelialdysfunctionandlowgradeinflammationinthetransitiontorenalreplacementtherapy
AT tomcornelis endothelialdysfunctionandlowgradeinflammationinthetransitiontorenalreplacementtherapy
AT marielleacjgelens endothelialdysfunctionandlowgradeinflammationinthetransitiontorenalreplacementtherapy
AT marcmhhermans endothelialdysfunctionandlowgradeinflammationinthetransitiontorenalreplacementtherapy
AT constantijnjamkonings endothelialdysfunctionandlowgradeinflammationinthetransitiontorenalreplacementtherapy
AT jeroenbvandernet endothelialdysfunctionandlowgradeinflammationinthetransitiontorenalreplacementtherapy
AT frankmvandersande endothelialdysfunctionandlowgradeinflammationinthetransitiontorenalreplacementtherapy
AT caspergschalkwijk endothelialdysfunctionandlowgradeinflammationinthetransitiontorenalreplacementtherapy
AT frankstifft endothelialdysfunctionandlowgradeinflammationinthetransitiontorenalreplacementtherapy
AT jorisjjmwirtz endothelialdysfunctionandlowgradeinflammationinthetransitiontorenalreplacementtherapy
AT jeroenpkooman endothelialdysfunctionandlowgradeinflammationinthetransitiontorenalreplacementtherapy
AT remyjhmartens endothelialdysfunctionandlowgradeinflammationinthetransitiontorenalreplacementtherapy
_version_ 1714806200793563136